What is the current stock price of Entera Bio Ltd. (ENTX)?

As of the latest market data, Entera Bio Ltd. (ENTX) is trading at $1.15. The stock has seen a loss of 0.00% today.

Does Entera Bio Ltd. (ENTX) pay a dividend?

Based on current data, Entera Bio Ltd. does not have a confirmed active dividend policy.

What is the market cap of Entera Bio Ltd.?

The current market capitalization of Entera Bio Ltd. (ENTX) is approximately unavailable.

ENTX

Entera Bio Ltd.·Healthcare

1.15

0.000%(+0.00)

Market Closed

1.38

20.000%(+0.23)

After Hours

Last Updated: — ET

52W L: $0.9152W H: $3.22

ENTX NEWS

prnewswire.com

4d ago

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

MIAMI, April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd.

globenewswire.com

Apr 2

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement for a private placement (the “Private Placement”) led by funds affiliated with BVF Partners L.P. (“BVF”).

feeds.benzinga.com

Mar 30

Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED)

Editor's Note: The future prices of benchmark tracking ETFs and the headline were updated in the story. U.S. stock futures rose on Monday following Friday's sharp sell-off. Futures of the major benchmark indices were higher after they entered the correction territory last week, falling more than 10% below their 52-week highs.

benzinga.com

Mar 30

Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In Focus

U.S. stock futures rose on Monday following Friday's sharp sell-off. Futures of the major benchmark indices were higher after they entered the correction territory last week, falling more than 10% below their 52-week highs.

globenewswire.com

Mar 27

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026

globenewswire.com

Mar 4

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following successful bridging study Topline data anticipated in the second half of 2028, approximately one year earlier than previously expected; Entera commits to a 12-month extension study to run in parallel with potential NDA review TEL AVIV, March 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced the submission to the U.S. Food and Drug Administration (FDA) of a clinical amendment providing a streamlined Phase 3 protocol, statistical analysis plan (SAP), and open-label extension synopsis to the Company's Investigational New Drug (IND) 505(b)(2) submission, to evaluate EB613 (Oral PTH(1-34), teriparatide).

Company Profile

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2018-06-28

Beta

1.54

Websitewww.enterabio.com↗